The ACC, AHA, and other organizations have released updated appropriate use criteria for coronary revascularization. The 2012 Appropriate Use Criteria for Coronary Revascularization Focused Update incorporates data from the SYNTAX trial on the indications for PCI and CABG in patients with symptomatic, multivessel disease, as well as data from the CathPCI registry. Here are some of the…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Although PCI has a small, early mortality benefit compared to CABG in high-risk patients, after the first year a striking survival advantage for CABG develops, according to results of the ASCERT study, presented on Monday at the annual meeting of the Society of Thoracic Surgeons (STS). Fred Edwards presented the high-risk subset of ASCERT (ACCF-STS Database…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

According to a recent meta-analysis of studies in patients undergoing PCI, rates of in-hospital mortality and emergency CABG for primary and non-primary PCI were similar at centers with and without on-site surgery.  At least, that’s the story the press is spreading around. However, several caveats should be noted . . . 1. The study included…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

In 2006, the Occluded Artery Trial (OAT) showed no benefit of routine PCI in patients with persistently occluded infarct-related arteries that were identified at least one day after an MI. According to a recent study, led by Judith Hochman, OAT has had minimal impact on clinical practice. We asked Hochman and two other experts why…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

The Occluded Artery Trial (OAT) demonstrated no benefit of routine PCI in persistently occluded infarct-related arteries identified more than 24 hours after MI. These results were incorporated into the revised guidelines for STEMI, NSTEMI, and PCI (published in 2007 and 2008) as a class III recommendation (i.e., not indicated and inappropriate). The senior investigator for…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

The CardioExchange editors have asked a panel of experts to weigh in on a new study published in JAMA. It showed that nearly all the acute percutaneous coronary interventions (PCIs) in the National Cardiovascular Data Registry from June 2009 through September 2010 were warranted, according to “appropriate use criteria” for coronary revascularization. However, the study…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

According to an analysis of data from the National Cardiovascular Data Registry (NCDR), nearly all (98.6%) acute PCIs (i.e., those done for STEMI, NSTEMI, and unstable angina) were classified as appropriate. For nonacute indications, however, only 50% were classified as appropriate; 38% were of uncertain appropriateness, and 12% were deemed inappropriate. Dig under the hood and…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Only half of all PCIs performed for nonacute cases have a definite indication, according to a report from the National Cardiovascular Data Registry published in JAMA. Paul Chan and colleagues analyzed data from more than half a million PCI procedures performed between July 1, 2009 and September 30, 2010. Out of 500,154 PCIs, they found…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

The editors at CardioExchange have again asked a panel of experts to respond to a clinically important study. This time it was a retrospective cohort study, published in JAMA, of door-in to door-out (DIDO) times for patients with ST-segment-elevation MI who had been admitted to one hospital and then were transferred to another center for…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

A small study from Poland raises the possibility that supplements containing omega-3 fatty acids may have beneficial effects when given to PCI patients already taking aspirin and clopidogrel. The investigator-initiated study randomized 54 PCI patients to either 1 g per day of n-3 PUFA daily or placebo for one month. The results have been published…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.